




PHARMACEUTICAL 2023

Immix Biopharma Inc.
Rank 127 of 446





PHARMACEUTICAL 2023

Immix Biopharma Inc.
Rank 127 of 446

The relative strengths and weaknesses of Immix Biopharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Immix Biopharma Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 114% points. The greatest weakness of Immix Biopharma Inc. is the variable Net Income, reducing the Economic Capital Ratio by 32% points.

The company's Economic Capital Ratio, given in the ranking table, is 173%, being 130% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	14,898
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,273
Liabilities, Non-Current	0
Other Assets	6.7
Other Compr. Net Income	-38
Other Expenses	10
Other Liabilities	475
Other Net Income	-0.50
Other Revenues	0
Property and Equipment	3.6
Research and Development	4,196
Selling, General and Administrative Expense	4,023

Output Variable	Value in 1000 USD
Assets	14,908
Liabilities	1,748
Expenses	8,229
Revenues	0
Stockholders Equity	13,160
Net Income	-8,230
Comprehensive Net Income	-8,249
Economic Capital Ratio	173%